CD40-CD40L interactions in platelet activation

• References

• 1 Korthauer U, Graf D, Mages HW. et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993; 361: 539-41.
• 2 Novo S, Basili S, Tantillo R. et al. Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis. Stroke 2005; 36: 673-5.
• 3 Falco A, Romano M, Iapichino L. et al. Increased soluble CD40 ligand levels in cystic fibrosis. J Thromb Haemost 2004; 2: 557-60.
• 4 Roselli M, Mineo TC, Basili S. et al. Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer Res 2004; 10: 610-4.
• 5 Andre P, Prasad KS, Denis CV. et al. CD40L stabilizes arterial thrombi by a β 3 integrin–dependent mechanism. Nat Med 2002; 8: 247-52.
• 6 Henn V, Slupsky JR, Gräfe M. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
• 7 Prasad KS, Andre P, Yan Y. et al. The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Curr Opin Hematol 2003; 10: 356-61.
• 8 Inwald DP, McDowall A, Peters MJ. et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003; 92: 1041-8.
• 9 Henn V, Steinbach S, Büchner K. et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-54.
• 10 Prasad KS, Andre P, He M. et al. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci USA 2003; 100: 12367-71.
• 11 Crow AR, Leytin V, Starkey AF. et al. CD154 (CD40 ligand)-deficient mice exhibit prolonged bleeding time and decreased shear-induced platelet aggregates. J Thromb Haemost 2003; 1: 850-2.
• 12 Langer F, Ingersoll SB, Amirkhosravi A. et al. The role of CD40 in CD40L- and antibody-mediated platelet activation. Thromb Haemost 2005; 93: 1137-46.
• 13 Yazdany J, Davis J. The role of CD40 ligand in systemic lupus erythematosus. Lupus 2004; 13: 377-80.
• 14 Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004; 13: 391-7.